Genenta, Evolving into Saentra Forge, Announces CEO’s Appointment by the Italian Government to the Board of Guarantors of the Italian Academy at Columbia University

Genenta, Evolving into Saentra Forge, Announces CEO’s Appointment by the Italian Government to the Board of Guarantors of the Italian Academy at Columbia University




Genenta, Evolving into Saentra Forge, Announces CEO’s Appointment by the Italian Government to the Board of Guarantors of the Italian Academy at Columbia University

MILAN, March 13, 2026 (GLOBE NEWSWIRE) — Genenta Science S.p.A. (Nasdaq: GNTA) transforming to Saentra Forge (Nasdaq: SAEN)1, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian national-security-related technologies, today announced that Pierluigi Paracchi, CEO of the Company, has been appointed as a member of the Board of Guarantors of the Italian Academy for Advanced Studies in America, the prestigious center for advanced scholarship hosted at Columbia University in New York, dedicated to promoting Italian culture, research, and intellectual exchange between Italy and the United States.

The appointment was conferred by Deputy Prime Minister and Foreign Minister Antonio Tajani and transmitted by the Ambassador of Italy to the United States, Marco Peronaci. The Board of Guarantors is composed of twelve members: six appointed by the Italian Government and six by Columbia University.

The Board of Guarantors plays an important role in supporting the activities of the Academy and its Director, helping preserve the institution’s high standards of academic and cultural excellence and strengthening its ties with Italian institutions. Founded in 1991 with the support of the Italian Republic, the Italian Academy for Advanced Studies in America is an interdisciplinary research center at Columbia University dedicated to fostering dialogue and collaboration between scholars, artists, and intellectuals from Italy and around the world. Through fellowships, research programs, conferences, and public events, the Academy promotes the study and dissemination of Italian culture and thought while encouraging transatlantic intellectual exchange.

I am deeply honored by this appointment to the Board of Guarantors of the Italian Academy at Columbia University, an institution that plays a vital role in strengthening intellectual and cultural ties between Italy and the United States,” said Pierluigi Paracchi. “As a CEO of the Company and Chairman of Fondazione Praexidia, I have been working to promote Italy’s strategic technological sectors — from defense and aerospace to biotechnology. I believe that connecting science, industry, and international collaboration is critical to a country’s long-term competitiveness, and that this perspective aligns closely with the Academy’s mission and can contribute to deepening dialogue between the Italian scientific and cultural ecosystem and leading academic institutions in the United States.”

For additional information on the governance of the Italian Academy, please visit: https://italianacademy.columbia.edu/content/governance-academy

About: Genenta Science (Nasdaq: GNTA), which will be renamed as Saentra Forge (Nasdaq: SAEN, pending effectiveness), will be a next-generation strategic consolidator focused on privately held specialized companies operating in Italian national security regulated sectors, with activities spanning cybersecurity, defense, aerospace, and biotechnology/biosecurity.

Forward-Looking Statements. Statements in this press release contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Genenta’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict, including risks related to the transition to Saentra Forge, the expansion to a sovereign-aligned industrial consolidator, the legal proceedings with ENEA Tech, the funding provided by the recently acquired Mandatory Convertible Bond, the Phase 1/2a clinical trial for newly diagnosed GBM patients with uMGMT-GBM or any related studies, as well as Genenta’s ability to establish partnerships and fund its research and development plans. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in Genenta’s Annual Report on Form 20-F for the year ended December 31, 2024, and Genenta’s material disclosures on Form 6-K dated January 26, 2026, both filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of the date of this announcement, and Genenta undertakes no duty to update such information except as required under applicable law. This press release discusses product candidates that are under preclinical or clinical evaluation and that have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. Until finalized in a clinical study report, clinical trial data presented herein remain subject to adjustment as a result of clinical site audits and other review processes. No representation is made as to the safety or effectiveness of these product candidates or the use for which such product candidates are being studied. Temferon™ is an investigational product candidate for which the effectiveness and safety have not been established. In addition, Temferon™ is not approved for use in any jurisdiction.

Genenta Science Media
Tiziana Pollio, Mobile: +39 348 23 15 143
e.mail: tiziana.pollio@genenta.com

___________________
1
The new corporate name and the new Nasdaq ticker symbol will become effective upon official Notary filing in Italy, presuming approval by its shareholders at a Shareholders’ Meeting scheduled for March 25-26, 2026.

Novonesis issues EUR 1.7 billion senior unsecured notes

Novonesis issues EUR 1.7 billion senior unsecured notes




Novonesis issues EUR 1.7 billion senior unsecured notes

On March 12, 2026, Novonesis, through Novozymes A/S, successfully priced and closed an aggregate principal amount of EUR 1.7 billion senior unsecured notes (the “Notes”). The issuance was completed under the newly established EUR 4 billion Euro Medium Term Note (EMTN) Programme, dated March 10, 2026.

The Notes will be issued on March 19, 2026, and listed on the Luxembourg Stock Exchange. This inaugural issuance consists of three tranches with maturities ranging from 4 to 11 years and fixed interest rates ranging from 3.25% to 4.00%.

Novonesis has been rated A- (stable outlook) by Standard & Poor’s (S&P).

The net proceeds from the transaction will be used to refinance existing debt and for general corporate purposes.

For further details about the EMTN Programme and this issuance, please visit our website.

Contact information

Investor Relations                                                      
Tobias Bjorklund                             +45 3077 8682                                tobb@novonesis.com
Anders Enevoldsen                         +45 5350 1453                                adev@novonesis.com

Treasury                                         
Frants Bisgaard Pedersen              +45 3077 0342                                fbp@novonesis.com

Media Relations                            
Jens Gamborg                                 +45 3077 7182                                 jgam@novonesis.com

Attachment

Now Available: Fresh Bloom THCA Flower Subscription Box by The Hemp Doctor

Now Available: Fresh Bloom THCA Flower Subscription Box by The Hemp Doctor




Now Available: Fresh Bloom THCA Flower Subscription Box by The Hemp Doctor

Inside contents of the Fresh Bloom THCA Flower Subscription Box by The Hemp Doctor.

MOORESVILLE, N.C., March 13, 2026 (GLOBE NEWSWIRE) — The Hemp Doctor introduces the Fresh Bloom THCA Flower Subscription Box, a monthly drop of hand-selected flower and pre-rolls delivered to your door, including limited-run strains not always sold individually.

Branded in The Hemp Doctor’s signature blue and green packaging with a bold orange wave design, the Fresh Bloom subscription box offers a rotating selection of expertly chosen THCA flower and infused pre-rolls, all at a 30% subscriber discount.

Each monthly box includes:

Subscribers will also receive smoke session essentials, including a 6-pack of RAW cones and matches. While supplies last, select boxes will feature exclusive stickers and surprise merchandise.

Each product included in the subscription undergoes third-party laboratory testing, with Certificates of Analysis (COAs) available for transparency.

With a retail value starting at $135 per box, subscribers receive a discounted price of $95 per month. A two-order minimum applies to all subscriptions.

“Fresh Bloom was designed for customers who want variety, exclusivity, and access to limited-run THCA flower strains that may not be available elsewhere,” said Robert Shade, Founder and CEO of The Hemp Doctor. “Our in-house experts curate each drop to ensure quality, freshness, and standout genetics in every shipment.”

The THCA Flower Subscription Box is now available through The Hemp Doctor’s online store. Customers can enroll through the Subscribe & Save page to secure their monthly delivery.

Also Available: Expanded THCA Subscription Options

Beyond the THCA Flower Box, The Cultivar Club offers tiered subscriptions for every style.

  • The Flower Connoisseur Box ($119.95/mo) includes premium flower, concentrates, and infused pre-rolls with rotating dealer’s-choice selections.
  • The Pre-Rolls Subscription Box ($89.98/mo) delivers a curated mix of sugar diamond, bubble hash, and classic pre-rolls with smoke session essentials.

Availability and age requirements vary by jurisdiction; customers must comply with local laws and confirm eligibility prior to purchase.

About The Hemp Doctor

The Hemp Doctor has been providing quality hemp-derived products since 2018. The North Carolina-based company is known for offering cannabinoid products ranging from premium THCA flower to pre-rolls, concentrates, Delta 9 gummies, vapes, and more.

The company stands out for its dedication to producing quality products paired with customer satisfaction. With over 250,000 returning customers, thousands of subscribers, 10,000+ reviews, and a Trustpilot rating of 4.6 out of 5 stars, The Hemp Doctor has positioned itself as a leader in the industry.

The Hemp Doctor prioritizes consumer safety, with products tested by independent third-party laboratories and supported by available certificates of analysis (COAs).

For media inquiries, interviews, or additional information, please contact:

Tara Phoenix
tara@thehempdoctor.com
+1 917-797-8347

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/59bf2866-f959-4af6-ad82-3dbac0312a3a

IBA Notice of Full Year 2025 Results and Conference Call

IBA Notice of Full Year 2025 Results and Conference Call




IBA Notice of Full Year 2025 Results and Conference Call

FY25 results webcast to take place on
Friday, 27 March 2026 at 3pm CET

Louvain-la-Neuve, Belgium, 13 March 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, announces today that it will publish its consolidated results for the full year 2025 on Friday, 27 March 2026 at 7am CET.

Conference Call Information

IBA’s management team will host team will host a conference call and webcast conducted in English to present the half year results, followed by a Q&A session.

The conference call will be held on Friday, 27 March 2026 at 3pm CET / 2pm BST / 10am EDT / 7am PDT as a Teams webinar. To attend the webcast, register via this link.

The presentation will be available on IBA’s investor relations website and on: https://www.iba-worldwide.com/iba-full-year-2025-results-press-release-conference-call  shortly before the call.

To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.

***ENDS***


About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered as one of the most advanced forms of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,100 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com

CONTACTS

Thomas Pevenage
Investor relations
+32 10 475 890
investorrelations@iba-group.com

Olivier Lechien
Corporate Communication Director
+32 10 475 890
communication@iba-group.com

Attachment

Medacta Group SA: Medacta Group reports record results in Full Year 2025 and upgrades mid-term guidance

Medacta Group SA / Key word(s): Annual Results/Annual Results

Medacta Group SA: Medacta Group reports record results in Full Year 2025 and upgrades mid-term guidance

13-March-2026 / 07:00 CET/CEST

Release of an ad hoc announcement pursuant to Art. 53 LR

The issuer is solely responsible for the content of this announcement.


 

Media Release – Ad-hoc announcement pursuant to Art. 53 LR                          

 

Medacta Group reports record results in Full Year 2025 and upgrades mid-term guidance

 

  • FY 2025 revenue accelerated to Euro 683.8 million, up 18.5% in c.c.1 or 15.8% in Euro
  • Adjusted EBITDA grew by 19.1% to Euro 190.8 million
  • Adjusted EBITDA margin advanced to 29.0% in c.c. 1 up 190 bps yoy
  • Net profit rose by 31.0% yoy to Euro 95.5 million incl. one-off gains
  • Operating cash flow grew by 42.5% to Euro 152.7 million
  • The Board of Directors is proposing a distribution of CHF 1.10 per share (2024: CHF 0.69), an increase of 59.4% yoy
  • Outlook 2026: Medacta is targeting a revenue growth in the range of 10% to 14% in constant currency and an expansion of the adjusted EBITDA margin of around 50bps vs. the prior year (27.9%), in constant currency, subject to unforeseen events.
  • Mid-term outlook: Revenue compound annual growth rate (CAGR) (2024–2027E) in constant currency is expected to range between 12% and 15%, with a gradual improvement of the adjusted EBITDA margin vs. 2025, in constant currency, subject to unforeseen events.

 

CASTEL SAN PIETRO, 13 March 2026 – Medacta Group SA (“Medacta”, SIX: MOVE) today announces its full year 2025 results.

Francesco Siccardi, CEO of Medacta, commented: “I am very pleased to report another year of strong organic sales growth in the high teens, together with a significant expansion of our adjusted EBITDA margin. These industry leading results confirm the unique position of Medacta. Our vigorous focus on differentiating innovations for minimally invasive techniques and personalized solutions, the surgeon-specific structured medical education and the constant expansion of our sales force are the key pillars of our successful strategy. I thank the entire Medacta team for its efforts in delivering such excellent results.”

 

Our achievements in 2025

2025 marks Medacta’s 10 years of success of Kinematic Alignment in combination with Medacta’s Ball-in-Socket design for total knee replacement. This was a milestone that underscores our dedication to sustainable innovation and improving patient outcome. Kinematic Alignment is a surgical technique designed to restore the natural knee function to its pre-arthritic state. This innovative approach has gained the attention and continues to find a growing consensus in the global orthopedic community.  

At the beginning of March 2025, Medacta announced the acquisition of Parcus Medical, a Florida based specialist provider of sports medicine and arthroscopy solutions. The acquisition excellently complements Medacta’s portfolio in sports medicine. Parcus Medical is integrated into Medacta’s Sportsmed within the Extremities business line. As part of the acquisition, Medacta also took over Parcus’ Medical US manufacturing site in Sarasota (Florida), allowing Medacta to also be vertically integrated in Sportsmed and to have the first non-Swiss based manufacturing plants. The acquisition of Parcus Medical contributed approximately 1.5% to Group revenue in 2025.

In 2025, Medacta progressed to further strengthen and optimize its supply chain. Medacta has almost finalized its new fully automated warehouse in Italy. This new setup will facilitate and reduce handling costs primarily in Europe, Middle East and Africa (EMEA).

In early September 2025, Medacta completed the first phase of the planned extension of its production and office site in Rancate, Ticino, Switzerland.

The company will continue its expansion plan in 2026, aiming to accommodate increased demand to support future growth, while creating numerous new jobs.

In 2025, Medacta added another 258 employees globally, reaching 2’165 employees in total. 

 

Key figures

(Euro million, except for earnings per share data) 31.12.2025 31.12.2024
Revenues 683.8 590.6
Gross profit 458.7 399.4
Profit for the period 95.5 72.9
Alternative performance measures    
(Euro million) 31.12.2025 31.12.2024
EBITDA 201.5 156.6
Adjusted EBITDA* 190.8 160.2
Adjusted EBITDA margin* 27.9% 27.1%
Operating cash flow 152.7 107.1
Free cash flow 15.7 8.3

 

(Euro million, except for employees) 31.12.2025 31.12.2024
Total assets 917.6 792.2
Total equity 456.6 379.7
Equity ratio 49.8% 47.9%
Number of employees 2’165 1’907

* Adjusted in 2025 for business combinations (Euro -11.3 million) and MDR transition costs (Euro 0.6 million). The reconciliation is provided in the “Alternative Performance Measures” section of the 2025 Annual Report.

 

Sustained above-market growth of 18.5% in constant currency

In 2025, Medacta recorded Group revenue of Euro 683.8 million, an increase of 18.5% in constant currency and an increase of 15.8% in Euro.

Medacta reported another year of outstanding growth in all geographic markets and continued superior growth across all business lines. This was achieved by the constant launch of our differentiating innovations across all business lines, our continued efforts in medical education and the attraction of new surgeons supported by our expanded sales force. 

Substantial revenue growth across all geographic areas

Medacta achieved substantial growth rates across all geographies. The largest contributions to growth came from Asia Pacific and North America, growing 23.0% and 19.0% respectively, followed by EMEA increasing 15.2%, all in c.c.. Latin America, which is the smallest geographic area, advanced a superb 42.2% in c.c..

Revenue distribution by geographic area:

(Euro million) FY 2025 FY  2024 Growth
in Euro
Growth in
constant currency
EMEA* 327.5 283.7 15.4% 15.2%
North America 204.5 179.3 14.1% 19.0%
Asia Pacific 134.8 115.1 17.1% 23.0%
Latin America 17.0 12.4 36.7% 42.2%
TOTAL 683.8 590.6 15.8% 18.5%

* Europe, Middle East and Africa

Excellent revenue expansion across all product lines

Hip revenues rose again in double-digits by 11.9% in c.c., to Euro 270.5 million, with particularly outstanding performance in Asia Pacific and North America. The growth was mainly the result of Medacta’s excellent Anterior Minimally Invasive Surgery (AMIS) platform, which allows an easily reproducible technique that delivers significant benefits to patients, surgeons as well as healthcare systems [1,2,3].

Knee revenues advanced by another outstanding 20.7% in c.c. to Euro 284.1 million. All geographic regions contributed to this growth, but mainly attributable to North America as well as EMEA. Next to Medacta’s personalized Kinematic Alignment platform MyKA, GMK SpheriKA, the first knee implant specifically designed for the Kinematic Alignment technique, promoted this excellent performance. In 2025, the global roll-out of GMK SpheriKA further advanced including the UK, Canada and Japan. 2025 saw an additional boost in the adoption of the NextAR Knee system as well as for cementless and SensiTiN, Medacta’s low-ion-release, options.

Extremities, which include both, Shoulder and Sportsmed, delivered another notable revenue growth of 46.2% in c.c. to Euro 72.1 million with both sub-businesses contributing to this great progress. In particular, Medacta’s Shoulder System, supported by advanced technologies such as Medacta’s MyShoulder patient-specific cutting guidesas well as NextAR Shoulder Augmented Reality surgical application delivered an excellent performance, achieving market leading position in key geographies.

Spine revenues increased by 12.2% in c.c. to Euro 57.0 million. The good acceleration was strongly sustained by Medacta’s technologies, particularly by NextAR Spine, and the Rod Optimizer platform, which support surgeons in designing the optimal surgical strategy based on each patient’s individual anatomy and helps to streamline the surgical workflow. An expansion was seen across all geographies but was primarily supported by EMEA as well as Asia Pacific.

Revenue distribution by business line:

(Euro million) FY  2025 FY 2024 Growth
in Euro
Growth in
constant currency
Hip 270.5 247.3 9.4% 11.9%
Knee 284.1 241.2 17.8% 20.7%
Extremities** 72.1 50.3 43.4% 46.2%
Spine 57.0 51.8 10.2% 12.2%
TOTAL 683.8 590.6 15.8% 18.5%

** Extremities include Shoulder and Sportsmed revenues

Gross profit

In 2025, gross profit advanced to Euro 458.7 million compared to Euro 399.4 million in 2024 reflecting an increase of 14.8% year-on-year. The corresponding gross profit margin was 67.1% compared to 67.6% over the same period in the previous year. The softening was the result of unfavorable FX impacts, which were partially offset by operational efficiencies realized. 

Adjusted EBITDA margin

Adjusted EBITDA grew to Euro 190.8 million compared to Euro 160.2 million in 2024, representing a year-on-year increase of more than 19%.  The corresponding 2025 adjusted EBITDA margin climbed to 29.0% in constant currency or 27.9% in Euro. This compares to an adjusted EBITDA margin of 27.1% in Euro in 2024. The margin expansion was the result of efficiency gains and lower costs, mainly in sales and marketing as compared to the same time period last year. Reported EBITDA was Euro 201.5 million compared to Euro 156.6 million, an increase of 28.7% year-on-year.

Adjusted EBIT

Adjusted EBIT for the period rose to Euro 114.3 million compared to Euro 94.4 million in 2024, reflecting an increase of more than 21% against the previous year. The corresponding adjusted EBIT margin was 16.7% in 2025 compared to 16.0% in the prior year, representing an improvement of 70 basis points year-on-year.

Net profit for the year

In 2025, the net financial result was Euro -9.8 million versus Euro -3.1 million in the previous year. The Group’s effective tax rate was 17.2% in 2025.

Profit for the period increased by 31.0% to Euro 95.5 million compared to Euro 72.9 million in 2024. The increase was the result of a higher operating profit and the bargain purchase gain recognized on the Parcus acquisition. In 2025, the corresponding net profit margin was 14.0% compared to 12.3% in 2024.

Cash flow

Medacta delivered a cash flow from operating activities of Euro 152.7 million in 2025 compared to Euro 107.1 million in the same period in 2024, representing an increase of 42.5% year-on-year.

Capital expenditures amounted to Euro 137.0 million in 2025 versus Euro 98.9 million compared to 2024. A good 80% of capital expenditures were investments in instruments and production expansions to sustain future growth.

Free cash flow was Euro 15.7 million compared to Euro 8.3 million in 2024, reflecting an improvement of almost 90%.

Solid balance sheet

Medacta’s balance sheet remained robust at the end of December 2025. Total assets increased to Euro 917.6 million vs. Euro 792.2 million at the end of 2024. The equity ratio strengthened to 49.8% at the end of December 2025 compared to an equity ratio of 47.9% at the end of December 2024.

Net debt to adjusted EBITDA ratio improved to 0.88x at the end of 2025 compared to 0.99x at the end of 2024.

Dividend proposal

At the Annual General Meeting on 5 May 2026, the Board of Directors will propose a dividend distribution of 1.10 CHF per share (0.69 CHF in 2024), an increase of 59.4% against the prior year. 

 

Outlook 2026

Medacta is targeting a revenue growth in the range of 10% to 14% in constant currency and an expansion of the adjusted EBITDA margin of around 50bps vs. the prior year (27.9%), in constant currency, subject to unforeseen events.

Mid-term outlook

Revenue compound annual growth rate (CAGR) (2024–2027E) in constant currency is expected to range between 12% and 15%, with a gradual improvement of the adjusted EBITDA margin vs. 2025, in constant currency, subject to unforeseen events.

For further financial details, please refer to the 2025 Annual Report, which can be accessed at: https://www.medacta.com/EN/financial-reports-and-presentations

Webcast Today at 3:00 p.m. (CET)

Medacta Group SA will present its Full Year 2025 results during a webcast today at 3:00 p.m. (CET). The call will be hosted by Francesco Siccardi (CEO) and Corrado Farsetta (CFO) and will be held in English.

Live-Link:  https://87399.choruscall.eu/links/medacta260313.html

Dial-in numbers for conference call only:

Belgium: +32 28948063
Denmark: +45 32727525
France: +33 170918704
Germany: +49 6917415712
Ireland: +353 15269444
Italy: +39 02 802 09 11
Spain: +34 917699498
Sweden: +46 850510030
Switzerland: +41 225954728
UK: +44 1 212818004
USA: +1 718 7058796

  

Contact

Medacta
Anja Pomrehn
Group VP Sustainability and Investor & Media Relations
Phone: +41 91 696 14 95

pomrehn@medacta.ch

 

About Medacta

Medacta is a global key player specializing in the design, production, and distribution of innovative, personalized, and sustainable solutions for joint replacement, sports medicine, and spine surgery. Established in 1999 in Switzerland, Medacta is committed to improving the care and well-being of patients and maintains a strong focus on healthcare sustainability. Through close collaboration with expert surgeons globally, continuous investments in R&D, and the adoption of cutting-edge technologies, Medacta’s innovation prioritizes minimally invasive surgery and personalized solutions for every patient. Through the M.O.R.E. Institute, Medacta supports surgeons with a comprehensive and tailored program dedicated to the advancement of medical education. Medacta is headquartered in Castel San Pietro, Switzerland. Follow us on Medacta.com, Medacta TV, YouTube, LinkedIn and X.

 

Disclaimer

This media release has been prepared by Medacta Group SA (‘Medacta’ and together with its subsidiaries, ‘we’, ‘us’ or the ‘Group’). The information contained in the media release does not purport to be comprehensive and is not to be taken as containing any securities advice, recommendation, offer or invitation to subscribe for, purchase or redeem any securities regarding Medacta.

 Forward-looking information

This media release has been prepared by Medacta and includes forward-looking information and statements concerning the outlook for its business. These statements are based on current expectations, estimates and projections about the factors that may affect its future performance. These expectations, estimates and projections are generally identifiable by statements containing words such as ‘expects’, ‘believes’, ‘estimates’, ‘targets’, ‘plans’, ‘outlook’ or similar expressions. Although Medacta believes that its expectations reflected in any such forward-looking statement are based upon reasonable assumptions, it can give no assurance that those expectations will be achieved.

 Related Trademarks

Medacta Group Related Trademarks are registered at least in Switzerland. The products and services listed below may not be all-inclusive, and other Medacta products and services not listed below may be covered by one or more trademarks. The products and services below may be covered by additional trademarks not listed below. Note that Swiss trademarks may have foreign counterparts. AMIS®, GMK® SpheriKA, MyShoulder®, MyKA™, SensiTiN™, NextAR™, NextAR™ Spine.

 Notes

1)Alternative Performance Measures:

This media release contains certain financial measures of historical performance that are not defined or specified by IFRS, such as “constant currency”, “EBITDA”, “adjusted EBITDA”, “Free Cash Flow”, “adjusted Free Cash Flow”, “Net Debt” and “Leverage”. These Alternative Performance Measures (APMs) should be regarded as complementary information to, and not as a substitute for the IFRS performance measures. For definitions of APMs, together with reconciliations to the most directly reconcilable IFRS line items, please refer section headed “Alternative Performance Measures” of the 2025 Annual Report. The 2025 Annual Report is available and can be accessed at:

 https://www.medacta.com/EN/financial-reports-and-presentations .

 Above-market revenue growth:

This press release contains information that refers to “above-market revenue growth”, which is in reference to data from The Orthopaedic Industry Annual Report® published by Orthoworld® Inc., published May 2025.     

References

[1] Vasina PG, Rossi R, Giudice GM, Palumbi P. Hip arthroposthesis through the anterior minimally invasive approach. Sphera 2010;6(12) – Speciale Ortopedia

[2] Christofilopoulos P, Roussos C, Lädermann A, Lübbeke A, Hoffmeyer P. Socioeconomic aspects of total hip arthroplasty. A comparison between anterior minimally invasive surgery and standard lateral approach. Poster at the 12th EFORT Congress, Copenhagen, Denmark: 1-4 June 2011.

[3] Sebečić B, Starešinić M, Culjak V, Japjec M. Minimally invasive hip arthroplasty: advantages and disadvantages. Med Glas (Zenica). 2012 Feb;9(1):160-5. PMID: 22634930.


End of Inside Information


Language: English
Company: Medacta Group SA
Strada Regina
6874 Castel San Pietro
Switzerland
Phone: +41 91 696 6060
E-mail: info@medacta.ch
Internet: www.medacta.com
ISIN: CH0468525222
Listed: SIX Swiss Exchange
EQS News ID: 2290722

 
End of Announcement EQS News Service

2290722  13-March-2026 CET/CEST

Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results

Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results




Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results

VICTORIA, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) — Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the fourth quarter of 2025. All dollar values are in U.S. dollars unless stated otherwise.

“2025 was a pivotal year for Eupraxia. We achieved significant clinical milestones in the development of our lead program, EP-104GI, and strengthened our balance sheet with two recent financings, positioning us well for our next phase of growth” said James Helliwell, CEO of Eupraxia. “As we look ahead to an exciting year, we anticipate multiple clinical readouts from the ongoing RESOLVE trial and the initiation of additional clinical programs in new indications to further expand and strengthen our pipeline”

Recent Operational and Financial Highlights

  • On November 13, 2025, the Company announced additional 52-week follow-up data from the RESOLVE trial in eosinophilic esophagitis (“EoE”) demonstrating consistent results after dosing with EP-104GI.
  • On January 8, 2026, the Company announced positive tissue health data from its ongoing RESOLVE trial in EoE demonstrating near-complete improvement on biopsy. 
  • On February 20, 2026, the Company announced the closing of a public offering of Common Shares (the “Offering”). The Company issued 7,607,145 Common Shares at a price of $7.00 per Common Share for gross proceeds of approximately $63.2 million which included the issuance of 1,178,571 Common Shares upon full exercise of the option to purchase additional shares granted to the underwriters, and 1,428,571 Pre-Funded Warrants at a price of $6.99999 per Pre-Funded Warrant.

Fourth Quarter 2025 Financial Review

The Company incurred a net loss of $16.7 million for the three months ended December 31st, 2025, versus a net loss of $7.5 million for the three months ended December 31st, 2024. The increase in net loss was primarily due to an increase in research and development costs associated with the EP-104GI program and increased general and administrative costs.

The Company had cash of $80.5 million as of December 31st, 2025, up from $33.1 million at the end of the fourth quarter of 2024.

The Company anticipates that existing cash reserves and proceeds from the Offering and anticipated future exercise of in-the-money warrants, will be sufficient to fund the Company into the second half of 2028.

As of December 31st 2025, the Company had 51,939,206 common shares and 8,355,638 preferred shares outstanding.

Potential Impact of Tariffs

Management continues to monitor the North American trade situation that began with the February 2025 announcement by the U.S. government of proposed 25% tariffs on selected imported Canadian goods, and the subsequent Canadian announcement of planned retaliatory tariffs on selected imported U.S. goods. At present, U.S. tariffs are in flux following the recent U.S. Supreme Court decision regarding the scope of executive tariff authority that struck down certain tariffs that had been in place.

Eupraxia manufactures its clinical supplies of EP-104IAR and EP-104GI in the U.S. by a third-party. The Company expects to continue to access manufactured products from the U.S.

The Company maintains U.S. dollar balances to pay U.S. dollar expenses and to minimize the impact of short-term fluctuations in exchange rates.

Management continues to assess the potential direct and indirect impacts of tariffs, counter-tariffs and other trade protection measures on Eupraxia’s business and will take those steps it deems necessary to attempt to mitigate any impact as the situation evolves.

Financial Statements and Management Discussion & Analysis

Please see the audited consolidated financial statements and related MD&A for more details. The audited consolidated financial statements for the year ended December 31, 2025, and related MD&A have been reviewed and approved by Eupraxia’s Audit Committee and Board of Directors. For a more detailed explanation and analysis, please refer to the MD&A that has been filed under the Company’s profile on EDGAR at www.sec.gov and on SEDAR+ at sedarplus.ca and which is also available on the Company’s website at www.eupraxiapharma.com.

About Eupraxia Pharmaceuticals Inc.
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Diffusphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support extended duration of effect and delivery of drugs in a hyper-localized fashion, targeting only the tissues that physicians are wanting to treat. We believe the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the Diffusphere™ technology, versus the peaks and troughs seen with more traditional drug delivery methods. The precision of Eupraxia’s Diffusphere™ technology platform has the potential to augment and transform existing FDA-approved drugs to improve their safety, tolerability, efficacy and duration of effect. The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, to also be applicable in oncology, infectious disease and other critical disease areas.

Eupraxia’s EP-104GI is currently in a Phase 1b/2 trial, the RESOLVE trial, for the treatment of EoE. EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. This is a unique treatment approach for EoE. Eupraxia also recently completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. The trial met its primary endpoint and three of the four secondary endpoints. In addition, Eupraxia is developing a pipeline of later and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs. For further details about Eupraxia, please visit the Company’s website at: www.eupraxiapharma.com.

Notice Regarding Forward-looking Statements and Information
This news release includes forward-looking statements and forward-looking information within the meaning of applicable securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “is expected”, “expects”, “suggests”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes”, “potential” or variations (including negative and grammatical variations) of such words and phrases, or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements in this news release include statements regarding the Company’s next phase of growth; the expected cash runway to fund pipeline development and operations into the second half of 2028; the use of proceeds from the Offering; the anticipated proceeds from future exercise of in-the-money warrants; the Company’s expectation that it will continue to access manufactured products from the U.S.; the potential imposition of a new reciprocal tariff rate; the Company’s product candidates, including their expected benefits to patients with respect to safety, tolerability, efficacy and duration; the expectations around proceeding to clinical trials for the Company’s product candidates; the results gathered from studies and trials of Eupraxia’s product candidates and the timing of the release thereof; the potential for the Company’s technology to impact the drug delivery process; potential market opportunity for the Company’s product candidates; and potential pipeline indications. Such statements and information are based on the current expectations of Eupraxia’s management, and are based on assumptions, including but not limited to: future research and development plans for the Company proceeding substantially as currently envisioned; industry growth trends, including with respect to projected and actual industry sales; the Company’s ability to obtain positive results from the Company’s research and development activities, including clinical trials; and the Company’s ability to protect patents and proprietary rights. Although Eupraxia’s management believes that the assumptions underlying these statements and information are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this news release may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Eupraxia, including, but not limited to: risks and uncertainties related to the Company’s limited operating history; the Company’s novel technology with uncertain market acceptance; if the Company breaches any of the agreements under which it licenses rights to its product candidates or technology from third parties, the Company could lose license rights that are important to its business; the Company’s current license agreement may not provide an adequate remedy for its breach by the licensor; the Company’s technology may not be successful for its intended use; the Company’s future technology will require regulatory approval, which is costly and the Company may not be able to obtain it; the Company may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications; the Company’s clinical trials may fail to demonstrate adequately the safety and efficacy of its product candidates at any stage of clinical development; the Company may be required to suspend or discontinue clinical trials due to side effects or other safety risks; the Company completely relies on third parties to provide supplies and inputs required for its product candidates and services; the potential impact of tariffs on the cost of the Company’s active pharmaceutical ingredients and clinical supplies of EP-104IAR and EP-104GI; the Company relies on external contract research organizations to provide clinical and non-clinical research services; the Company may not be able to successfully execute its business strategy; the Company will require additional financing, which may not be available; any therapeutics the Company develops will be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect the Company’s ability to obtain regulatory approval in a timely manner, or at all; the impact of health pandemics or epidemics on the Company’s operations; the Company’s restatement of its consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on the Company’s common share price; and other risks and uncertainties described in more detail in Eupraxia’s public filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov). Although Eupraxia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement or information can be guaranteed. Except as required by applicable securities laws, forward-looking statements and information speak only as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or revise any forward-looking statement or information, whether as a result of new information, future events or otherwise.

For investor and media inquiries, please contact:
James Meikle, Eupraxia Pharmaceuticals Inc.
236.330.7084
jmeikle@eupraxiapharma.com

or

Kevin Gardner, on behalf of:
Eupraxia Pharmaceuticals Inc.
617.283.2856
kgardner@lifesciadvisors.com

SOURCE Eupraxia Pharmaceuticals Inc.

Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering

Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering




Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering

RICHMOND, Va., March 12, 2026 (GLOBE NEWSWIRE) — Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced the pricing of its offering of $450,000,000 aggregate principal amount of 0.625% convertible senior notes due 2031 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering was upsized from the previously announced offering size of $400,000,000 aggregate principal amount of notes. Indivior also granted the initial purchasers of the notes a 30-day option to purchase up to an additional $50,000,000 principal amount of notes. The sale of the notes to the initial purchasers is expected to settle on March 17, 2026, subject to customary closing conditions.

The notes will be senior, unsecured obligations of Indivior and will accrue interest at a rate of 0.625% per annum, payable semi-annually in arrears on March 15 and September 15 of each year, beginning on September 15, 2026. The notes will mature on March 15, 2031, unless earlier repurchased, redeemed or converted. Before December 16, 2030, noteholders will have the right to convert their notes only upon the occurrence of certain events. From and after December 16, 2030, noteholders will have the right to convert their notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. Indivior will settle conversions by paying or delivering cash and, if applicable, shares of its common stock.. The initial conversion rate is 24.0033 shares of common stock per $1,000 principal amount of notes, which represents an initial conversion price of approximately $41.66 per share of common stock. The initial conversion price represents a premium of approximately 35.0% over the last reported sale price of the common stock on The Nasdaq Global Select Market on March 12, 2026. The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events.

The notes will be redeemable, in whole or in part (subject to certain limitations), for cash at Indivior’s option at any time, and from time to time, on or after March 20, 2029 and on or before the 25th scheduled trading day before the maturity date, but only if the last reported sale price per share of Indivior’s common stock exceeds 130% of the conversion price for a specified period of time and certain other conditions are satisfied. The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. If certain events that constitute a “fundamental change” occur, then, subject to a limited exception, noteholders may require Indivior to repurchase their notes at a cash repurchase price equal to the principal amount of the notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the applicable repurchase date.

Indivior estimates that the net proceeds to it from the offering will be approximately $437.7 million (or approximately $486.4 million if the initial purchasers fully exercise their option to purchase additional notes), after deducting the initial purchasers’ discounts and commissions and Indivior’s estimated offering expenses. Indivior intends (1) to use approximately $239 million of the net proceeds from the offering together with approximately $102 million of cash on hand to repay borrowings under and terminate the note purchase agreement that governs its term loan and revolving credit facility, (2) to use approximately $75.0 million of the net proceeds from the offering to repurchase approximately 2.4 million shares of its common stock from certain purchasers of the notes concurrently with the pricing of the offering in privately negotiated transactions effected through one of the initial purchasers or an affiliate thereof, at a price per share equal to the last reported sale price per share of the common stock on The Nasdaq Global Select Market on March 12, 2026 and (3) the remainder of the net proceeds from the offering for general corporate purposes.

The concurrent repurchases of approximately $75.0 million of common stock described above may have resulted in the common stock trading at prices that were higher than would be the case in the absence of these repurchases, which may have resulted in a higher initial conversion price for the notes.

The notes were only offered to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act. The offer and sale of the notes and any shares of common stock issuable upon conversion of the notes have not been, and will not be, registered under the Securities Act or any other securities laws, and the notes and any such shares cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the notes or any shares of common stock issuable upon conversion of the notes, nor will there be any sale of the notes or any such shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful.

About Indivior

As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease. For more than 25 years, we have revolutionized the science of addiction medicine — developing treatments that help people move toward long-term recovery with independence and dignity. Building on this heritage, we are ushering in a new era, renewing our commitment to individuals living with OUD and carrying forward what matters most: compassion, integrity, and science. Together – with science, people living with OUD, public health champions, and communities, we are powering recovery and renewing hope.

Important Cautionary Note Regarding Forward-looking Statements

Certain statements contained herein are forward-looking statements. Forward-looking statements include, among other things, express and implied statements pertaining to: (i) whether Indivior will issue the notes; (ii) the timing of the closing of the offering; (iii) the expected amount and intended use of the net proceeds from the offering; (iv) Indivior’s expectations regarding the effects of the concurrent common stock repurchases; and (v) statements containing the words “believe,” “anticipate,” “plan,” “expect,” “intend,” “estimate,” “forecast,” “strategy,” “target,” “guidance,” “outlook,” “potential,” “project,” “priority,” “may,” “will,” “should,” “would,” “could,” “can,” “outlook,” the negatives thereof, and variations thereon and similar expressions. By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future. Actual results may differ materially from those expressed or implied in such statements because they relate to future events. For information about some additional risks and important factors that could affect our future results and financial condition, see the discussion of “Risk Factors” in our Annual Report on Form 10-K filed February 26, 2026 and our other filings with the SEC.

We have based the forward-looking statements in this release on our current expectations and beliefs concerning future events. Forward-looking statements contained in this release speak only as of the day they are made and, except as required by law, we undertake no obligation to update or revise any forward-looking statement.

For Further Information

Investors:
Jason Thompson
Indivior Pharmaceuticals
Tel: 804-402-7123
E-mail: jason.thompson@indivior.com

Media:
Cassie France-Kelly
Indivior Pharmaceuticals
Tel: 804-594-0836
E-Mail: Indiviormediacontacts@indivior.com

VitalHub Announces Updated Date for Fourth Quarter and Annual 2025 Results

VitalHub Announces Updated Date for Fourth Quarter and Annual 2025 Results




VitalHub Announces Updated Date for Fourth Quarter and Annual 2025 Results

TORONTO, March 12, 2026 (GLOBE NEWSWIRE) — Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) announced today that it has updated the date for the release of its financial results for the fourth quarter and year ended December 31, 2025.

The Company now expects to release its financial results on Wednesday, March 18, 2026, after market close. VitalHub will host a conference call to discuss the results on Thursday, March 19 at 8:00am EST. The change in timing reflects the need for additional time to finalize the Company’s annual financial statements.

To register for the conference call please visit: https://us06web.zoom.us/webinar/register/WN_k8_Av320RimXFXW0CFzQEA

About VitalHub

VitalHub is a leading software company dedicated to empowering health and human services providers globally. VitalHub’s comprehensive product suite includes electronic health records, operational intelligence, and workforce automation solutions that serve over 1,300 clients across the UK, Canada, and other geographies. The Company has a robust two-pronged growth strategy, targeting organic opportunities within its product suite and pursuing an aggressive M&A plan. VitalHub is headquartered in Toronto with over 700 employees globally, across key regions and the VitalHub Innovations Lab in Sri Lanka. For more information about VitalHub (TSX:VHI) (OTCQX:VHIBF), please visit www.vitalhub.com and LinkedIn.

Contact Information

Christian Sgro, CPA, CA, CFA
Head of IR and M&A Specialist
(365) 363-6433
christian.sgro@vitalhub.com

Dan Matlow
Chief Executive Officer, Director
(416) 727-9061
dan.matlow@vitalhub.com

Surgery Partners, Inc. Names Lloyd Dean to Board of Directors

Surgery Partners, Inc. Names Lloyd Dean to Board of Directors




Surgery Partners, Inc. Names Lloyd Dean to Board of Directors

BRENTWOOD, Tenn., March 12, 2026 (GLOBE NEWSWIRE) — Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”) recently announced that Lloyd Dean has been appointed to serve as an independent director on its Board of Directors.

Mr. Dean is the former Chief Executive Officer of CommonSpirit Health, one of the largest nonprofit health systems in the United States, with 142 hospitals, over 1,000 care sites, 25,000 physicians, and 150,000 employees across 21 states. From 2019 to 2022, he led the formation and integration of CommonSpirit, advancing clinical quality, operational performance, and community health initiatives at national scale. Prior to CommonSpirit, Mr. Dean served as President and CEO of Dignity Health, where he strengthened patient experience, expanded partnerships, and elevated the organization’s leadership in delivering compassionate, high‑quality care.

A nationally recognized healthcare leader, Mr. Dean has long championed efforts to reduce health disparities, strengthen the health care workforce, and advance equitable access to care. He has served as an adviser to multiple Presidential Administrations on issues including the Affordable Care Act and COVID‑19 vaccination efforts. Mr. Dean has also held several federal and state appointments focused on public health, economic development, and workforce planning.

Mr. Dean serves on the boards of McDonald’s Corporation—where he chairs the Board Human Resources & Compensation Committee—Guidehouse, Nox Health, and Progyny, and is a Senior Advisor to Bain Capital. He holds a B.S. in sociology and a master’s degree in educational leadership from Western Michigan University, along with multiple honorary doctorates.

“We are honored to welcome Lloyd to the Surgery Partners Board,” said Blair Hendrix, Chairman of Surgery Partners’ Board of Directors. “Lloyd is a nationally respected leader with deep experience advising health systems and shaping public policy. His insights will be invaluable as we continue to expand high‑quality, cost‑effective surgical care across the country.”

“I am excited to join the Board at a time of meaningful growth and opportunity for Surgery Partners,” said Mr. Dean. “The Company is well positioned to continue leading the shift toward high‑value outpatient surgical care, and I look forward to supporting its important mission.”

About Surgery Partners

Headquartered in Brentwood, Tennessee, Surgery Partners is a leading healthcare services company with a differentiated outpatient delivery model focused on providing high quality, cost effective solutions for surgical and related ancillary care in support of both patients and physicians. Founded in 2004, Surgery Partners is one of the largest and fastest growing surgical services businesses in the country, with more than 200 locations in 30 states, including ambulatory surgery centers, surgical hospitals, multi-specialty physician practices and urgent care facilities. For additional information, visit www.surgerypartners.com.

Contact

Surgery Partners Investor Relations

(615) 234-8940

IR@surgerypartners.com

GlycoPezil Supplement Claims Evaluated – Complete Investigation of the Blood Sugar Support Ingredients

GlycoPezil Supplement Claims Evaluated – Complete Investigation of the Blood Sugar Support Ingredients




GlycoPezil Supplement Claims Evaluated – Complete Investigation of the Blood Sugar Support Ingredients

A 2026 consumer research report examining GlycoPezil’s ingredient research references, proprietary blend structure, pricing transparency, and verification considerations for adults researching blood sugar support supplements

Lakeland, FL, March 12, 2026 (GLOBE NEWSWIRE) — This article contains affiliate links. If a purchase is made through these links, a commission may be earned at no additional cost to the buyer. This article is an informational overview and does not constitute medical, health, or dietary advice. All product details described below are stated as presented by the company and should be verified directly on the official website before any purchasing decision.

In this report, the word “effectiveness” refers strictly to how GlycoPezil’s marketing language describes potential outcomes — not to any clinically proven result. No published clinical trial appears to have evaluated GlycoPezil as a proprietary formula.

If you’ve been researching blood sugar support supplements lately, GlycoPezil is likely one of the names you’ve come across. The product has been drawing real consumer attention — particularly among adults researching ways to support metabolic wellness and glucose balance over time.

Consumers searching terms such as “GlycoPezil review,” “does GlycoPezil work,” “GlycoPezil ingredients,” or “GlycoPezil blood sugar supplement” are typically trying to answer one specific question: how does the product’s marketing language connect to the actual ingredient research? That’s exactly what this report examines.

GlycoPezil Supplement Claims Evaluated Complete Investigation of the Blood Sugar Support Ingredients

This report examines the company’s published ingredient information, scientific references cited on the official website, and publicly available policy details so readers can independently evaluate the product’s claims.

Current product details, pricing, and terms are available here: View the current GlycoPezil offer (official GlycoPezil page).

Individual results vary. Dietary supplements are not substitutes for balanced nutrition, regular physical activity, or professional medical guidance. Consult a qualified healthcare provider before starting any new supplement, especially if you are managing blood sugar concerns or taking prescription medications.

What Is GlycoPezil

GlycoPezil is a dietary supplement marketed as a blood sugar support formula delivered in liquid drop form. The company’s product page describes it as a proprietary blend of eight carefully selected ingredients designed to support healthy blood sugar levels and overall metabolic well-being, positioning the formula for adults who want to maintain balanced glucose levels as part of a daily wellness routine.

According to the official website, GlycoPezil is manufactured in the United States from a combination of domestic and foreign-sourced ingredients. The product page states that the formula is produced in an FDA-registered facility following GMP (Good Manufacturing Practices) guidelines. It’s worth understanding what that means: FDA registration of a manufacturing facility confirms it is subject to federal inspection and operates under manufacturing standards. It is not an FDA review, approval, or endorsement of the product itself or any claims made about it.

The company describes GlycoPezil as a natural formula with plant-based ingredients, marketed as non-habit forming and easy to incorporate into a daily routine in drop form. The product is sold exclusively through the official website, with the company advising consumers that product authenticity and refund eligibility may not be guaranteed through unauthorized third-party sellers.

GlycoPezil Ingredient Claims: What the Company States and How to Evaluate It

The central marketing positioning of GlycoPezil connects its proprietary ingredient blend to support for healthy blood sugar levels, energy support, and metabolic balance. The company’s product page describes the formula as designed to help the body maintain balanced glucose levels and support metabolic well-being, citing clinical research as the basis for its ingredient selection.

The product’s promotional materials describe certain ingredient mechanisms in strong biological terms, including references to hormone signaling pathways and metabolic activity. These descriptions appear in the company’s marketing narrative and should not be interpreted as independently verified clinical outcomes without controlled studies on the finished formulation. They reflect how the brand positions its ingredients — not conclusions drawn from clinical trials evaluating GlycoPezil as a complete product.

There is genuine published research on individual compounds associated with blood sugar support categories. A substantial body of peer-reviewed literature covers nutrients such as Vitamin D, Vitamin C, B vitamins, and botanical extracts in the context of metabolic health and glucose regulation. GlycoPezil’s own scientific reference section cites published studies in this space, and those citations point to real peer-reviewed work.

The distinction between ingredient research and finished product testing is one of the most important factors when evaluating any dietary supplement. Studies cited in marketing materials typically examine isolated compounds under controlled conditions at specific dosages — not the proprietary blend contained in a specific supplement formula. That gap isn’t unique to GlycoPezil; it’s a category-wide reality. But it’s the single most important thing to understand when reading a supplement’s marketing claims alongside its referenced science.

As of this report, no published clinical trial appears to have evaluated GlycoPezil as a finished proprietary formula. Consumers searching for “GlycoPezil legit” or “GlycoPezil ingredients research” should carry that distinction clearly into their evaluation.

Additionally, some specific ingredient designations described in GlycoPezil’s marketing materials use terminology that does not appear in standard peer-reviewed scientific nomenclature. Consumers who want to cross-reference specific compound claims should verify ingredient names against recognized databases such as PubMed or the FDA’s dietary supplement ingredient directory before drawing conclusions about the underlying research basis.

What Published Blood Sugar Research Actually Covers

Understanding the broader ingredient research landscape puts GlycoPezil’s marketing claims in proper context — and gives a more useful answer than a simple yes-or-no on whether the product works.

Vitamin D has been studied extensively in relation to type 2 diabetes risk, beta cell function, and insulin sensitivity. Multiple peer-reviewed analyses have examined associations between Vitamin D status and metabolic outcomes, and GlycoPezil’s own reference section cites several of these studies directly.

Vitamin C has been evaluated in published research for its potential role in metabolic health and glucose management. Peer-reviewed narrative reviews have noted possible supportive effects for adults managing blood sugar concerns, with mechanisms often discussed in the context of oxidative stress reduction and fat metabolism support.

B vitamins, including B12, have been reviewed in published literature for their role in metabolic pathways and their relationship to diabetes-adjacent concerns, including nerve health and metabolic enzyme function.

In the botanical category, capsaicin — the active compound in cayenne — has peer-reviewed research examining effects on metabolism and glucose uptake. Green tea catechins, particularly EGCG, have accumulated evidence across multiple controlled studies on metabolic outcomes. Maca root (Lepidium meyenii) has been evaluated in randomized controlled trials for tolerability and safety, with acceptability research published in peer-reviewed journals.

These are real findings on real compounds. What they all have in common is that they tested isolated ingredients at known, disclosed dosages — often significantly higher than what a multi-ingredient proprietary blend can distribute across its full formula in a single serving. Treating those findings as proof of what a finished supplement will do would misrepresent what the research actually demonstrated.

That context isn’t meant to dismiss GlycoPezil’s ingredient selection. It’s meant to give you the accurate framework for understanding what the cited research does and doesn’t support.

GlycoPezil Proprietary Blend Structure: What It Means for You

GlycoPezil is formulated as a proprietary blend — a common structure across the supplement industry where the total blend volume is disclosed but individual ingredient amounts per serving are not. This protects the company’s formulation trade secrets, but it does limit your ability to compare each ingredient’s dosage against what clinical studies examined.

For context: published research on blood sugar-relevant nutrients and botanicals often examines single compounds at specific daily amounts. A multi-ingredient proprietary blend distributes its total volume across all listed ingredients simultaneously. Without disclosed individual amounts, there is no way to confirm or rule out research-level dosing from the label alone.

If knowing exact per-ingredient amounts matters to your purchasing decision, the most direct path is contacting the manufacturer directly. Some companies provide that information on request even when it isn’t listed publicly on the label.

Understanding proprietary blend structure won’t tell you whether a product is effective. What it does tell you is the exact boundary of what the label itself can confirm — which is a useful distinction to carry into any supplement purchase decision.

GlycoPezil Pricing and Purchase Structure

According to pricing information published on the official website at the time of this report, GlycoPezil is available in several multi-bottle packages. The company’s published pricing describes a 6-bottle option at $49 per bottle (listed total $294 with free US shipping), a 3-bottle option at $69 per bottle (listed total $207 with free US shipping), and a 2-bottle option at $89 per bottle (listed total $178 with a shipping charge).

According to the product page, all purchases are described as one-time payments with no automatic rebilling or subscription charges without explicit consent. The product page states that a majority of customers select the 6-bottle package as part of longer-term use plans described by the company.

Pricing and availability are subject to change. Readers can confirm current terms at the source: View the current GlycoPezil offer (official GlycoPezil page).

GlycoPezil Refund Policy: Reading the Full Terms Before You Buy

The company’s published materials reference a 60-day money-back guarantee. If you’re considering a purchase based on that guarantee, the complete return policy is worth reading carefully before you commit — specific conditions apply that differ from a straightforward full refund.

According to the return policy published on the official website at the time of this report, consumers requesting a refund should contact customer support by email at contact@customercs.com or by phone at +1 (507) 448-8190. The published policy states that return shipping costs are the customer’s responsibility and that the return process may take up to 30 days.

The policy also specifies that all bottles in the original order must be returned, that only sealed products are eligible for refund, and that a 30-day minimum usage period is required before a refund request will be accepted. A 15% restocking fee is deducted from the total refund amount, and shipping fees are described as non-refundable. Fulfilled orders cannot be canceled or refunded after shipping unless delivery denial upon arrival is confirmed, and chargebacks in progress eliminate refund eligibility through the company.

Retain all purchase confirmations and review the complete policy on the official website. The terms above are as published at the time of this report and are subject to change.

GlycoPezil Customer Testimonials: What the Company’s Own Disclosures Say

The official GlycoPezil website includes customer testimonials describing individual experiences with the product. The site’s own disclaimer states these examples may not represent typical results and should not be interpreted as guarantees of performance. The company explicitly notes that testimonials may not reflect the average buyer’s experience and are not intended to guarantee that any person will achieve the same or similar results.

Individual outcomes with dietary supplements vary based on baseline health, age, lifestyle factors, concurrent medications, and consistency of use. The results described in any testimonial reflect one person’s experience under their specific circumstances — not a predictable range across all users.

Who May Want to Research GlycoPezil Further

Based on the product’s published positioning and delivery format, GlycoPezil may be relevant to adults researching liquid-format blood sugar support supplements as one piece of a broader wellness approach that also includes balanced nutrition and regular physical activity.

Adults who rely heavily on transparent per-ingredient dosing for clinical comparison may find the proprietary blend structure limits that evaluation from the label alone — though asking the manufacturer directly is always an option. Anyone managing a diagnosed metabolic condition or taking prescription medications for blood sugar should speak with a healthcare provider before adding any supplement to their routine.

Dietary supplements are regulated differently from pharmaceutical drugs. The FDA does not evaluate supplement efficacy claims before products reach market. GlycoPezil’s own website confirms that its statements have not been evaluated by the Food and Drug Administration and that the product is not intended to diagnose, treat, cure, or prevent any disease.

View the current GlycoPezil offer (official GlycoPezil page)

Consumer Verification Checklist: What to Confirm Before Ordering

Read the complete refund policy before purchasing. The 60-day guarantee comes with a 30-day minimum usage requirement, a 15% restocking fee, return shipping at your cost, and a requirement that bottles be returned sealed. Knowing these terms upfront eliminates surprises if you decide to return the product.

Separate ingredient research from product research. GlycoPezil’s reference section links to published studies on individual nutritional compounds — not on GlycoPezil’s finished formula. That’s a meaningful distinction when setting expectations about what the science actually supports.

Cross-reference ingredient names with scientific databases. Some compound designations in the marketing materials don’t appear in standard peer-reviewed nomenclature. PubMed and the FDA’s dietary supplement ingredient directory are good places to start that verification.

Talk to your healthcare provider first. This is the most important step for anyone currently taking prescription medications for blood sugar management, living with diabetes or prediabetes, or managing related metabolic conditions. No dietary supplement should replace prescribed medical care, and a clinician who knows your health history is the right person to advise whether adding anything new makes sense for you.

Confirm current pricing and terms directly. Promotional pricing, multi-bottle offers, and refund terms can change without notice. Always verify on the official website before completing a purchase.

Consumer Questions About GlycoPezil

Is GlycoPezil FDA approved?

No — and that’s true of virtually all dietary supplements. Under current federal law, dietary supplements do not require FDA approval before they can be sold, and the FDA does not evaluate supplement efficacy claims prior to market entry. The website states that GlycoPezil is manufactured in an FDA-registered, GMP-certified facility. That refers to manufacturing standards and inspection eligibility — not FDA approval or endorsement of the product itself.

What ingredients does GlycoPezil contain?

The company describes GlycoPezil as an eight-ingredient proprietary blend formulated to support blood sugar balance. The scientific reference section on the product page cites published research covering Vitamin D, Vitamin C, B vitamins, and botanical compounds relevant to metabolic health. Consumers should verify the specific ingredient list on the official website and cross-reference any compound names with recognized scientific databases such as PubMed before drawing conclusions.

Can the research cited on the GlycoPezil website be verified?

Yes — the official website links to published peer-reviewed studies on individual nutritional compounds in the blood sugar and metabolic health space. Those studies can be looked up directly in PubMed or the relevant journal archives. The important thing to keep in mind is that those studies examined individual compounds at specific dosages under controlled conditions, not GlycoPezil’s proprietary formula as a finished product. That distinction matters when interpreting what the cited science does and doesn’t support.

Does GlycoPezil work for both men and women?

The company’s product page markets GlycoPezil broadly to adults seeking blood sugar support. Published research on individual compounds in this category has included both male and female study populations, though outcomes vary based on hormonal differences, baseline health, age, and other individual factors. A healthcare provider who knows your health history is better positioned than any supplement label to advise whether a product like this is appropriate for your situation.

What is the GlycoPezil refund policy?

The company’s published refund policy provides a 60-day window for requests, with several specific conditions: a 30-day minimum usage requirement, a 15% restocking fee, return shipping at the buyer’s cost, and a requirement that all bottles in the original order be returned in sealed condition. Review the complete return policy on the official website before purchasing and retain all order confirmations.

How long does GlycoPezil take to show results?

The company’s marketing language describes the formula as designed for consistent daily use over time, rather than for immediate results. Individual timelines depend on factors including baseline health, dietary habits, physical activity, age, and how consistently the product is used. The site’s own disclaimer notes that testimonial results may not reflect the typical buyer’s experience and should not be interpreted as guaranteed.

Where is GlycoPezil sold?

According to the company’s website, GlycoPezil is only available through its official website at glycopezilofficial.com. The company advises against purchasing through third-party marketplaces, noting that product authenticity and refund eligibility may not be guaranteed through unauthorized sellers.

What does “manufactured in an FDA-registered facility” mean?

An FDA-registered facility is a manufacturing site that has completed registration with the FDA as required by federal law and is subject to FDA inspection. GMP certification means the facility follows Good Manufacturing Practices for dietary supplements. Neither designation means the FDA has reviewed, tested, approved, or endorsed any specific product made at that location. They are manufacturing standards designations — not product safety or efficacy certifications.

Summary of Key Considerations

GlycoPezil is a dietary supplement marketed as a blood sugar support formula in liquid drop form, built around a proprietary blend of eight ingredients. The company cites published scientific research in its positioning, and the reference section includes citations to peer-reviewed work on individual nutritional compounds in the metabolic and glucose health space.

A few distinctions are worth carrying into any final decision. The cited research covers individual compounds studied in isolation — not GlycoPezil’s finished formula. No published clinical trial appears to have evaluated GlycoPezil as a complete formulation. Some ingredient designations in the marketing materials should be cross-referenced with scientific databases before being taken at face value. And the refund policy includes conditions — a 15% restocking fee, a 30-day minimum usage requirement, and buyer-paid return shipping — that differ meaningfully from a straightforward money-back guarantee.

The company states that GlycoPezil is manufactured under GMP standards in an FDA-registered facility, that all purchases are one-time payments with no automatic rebilling, and that the product is not intended to diagnose, treat, cure, or prevent any disease per the FDA disclaimer on the product’s own website.

Consumers who want to review full product details, current pricing, and published policy terms can do so directly. View the current GlycoPezil offer (official GlycoPezil page).

Contact Information

Product: GlycoPezil

Official Website: glycopezilofficial.com

Customer Support Email: contact@customercs.com

Customer Support Phone: +1 (507) 448-8190

Disclaimers

FDA Health Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult your physician before starting any new supplement, especially if you have existing health conditions, take medications, or are managing blood sugar concerns.

Professional Medical Disclaimer: This article is educational and does not constitute medical advice. GlycoPezil is a dietary supplement, not a medication. If you are currently taking prescription medications for blood sugar management, have existing health conditions, are pregnant or nursing, or are considering any major changes to your health regimen, consult your physician before starting GlycoPezil or any new supplement. Do not change, adjust, or discontinue any medications or prescribed treatments without your physician’s guidance and approval.

Results May Vary: Individual results will vary based on factors including age, baseline health condition, lifestyle factors, consistency of use, genetic factors, current medications, and other individual variables. While some customers report improvements, results are not guaranteed. Testimonials on the official website represent individual submitted experiences and, per the company’s own disclaimer, may not reflect the typical buyer’s experience.

FTC Affiliate Disclosure: This article contains affiliate links. If a purchase is made through these links, a commission may be earned at no additional cost to the buyer. This compensation does not influence the accuracy, neutrality, or integrity of the information presented. All descriptions are based on publicly available information from the official website and published research.

Pricing Disclaimer: All prices, discounts, promotional offers, and refund terms mentioned were accurate at the time of publication (March 2026) but are subject to change without notice. Always verify current pricing and full terms on the official GlycoPezil website before making any purchase decision.

Publisher Responsibility Disclaimer: The publisher of this article has made every effort to ensure accuracy at the time of publication based on publicly available information

CONTACT: Email: contact@customercs.com
Phone: +1 (507) 448-8190